FIRMAGON® (degarelix) is a treatment for men with advanced hormone-dependent prostate cancer.
The growth of prostate cancer is dependent on testosterone, so the goal of many treatments is to reduce testosterone levels. This can cause the cancer cells to grow more slowly or stop growing and can even reduce the size of the tumour.
FIRMAGON has a novel mechanism of action that is different from other hormonal therapies. It provides a fast and sustained suppression of testosterone without a testosterone surge, and it offers an exciting alternative to traditional GnRH agonist therapy.
DDAVP Melt® (desmopressin)
DDAVP® Melt (desmopressin) is indicated for the treatment of bedwetting in children, a condition that can be traumatic, affecting their well-being and self-esteem.
Bedwetting is usually caused by an overproduction of urine at night, and DDAVP Melt acts on the kidneys to reduce the amount of urine produced. DDAVP Melt is available in melts, a child-friendly, fast-melting tablet that dissolves when placed under the tongue, and in regular tablets.
Nocdurna® (desmopressin) is indicated for the treatment of adults who have to wake up during the night, up to four times, to urinate, a condition called nocturia.
Nocdurna® works by making the kidneys reabsorb more water, thereby producing less urine.